Introduction: The gluten dilemma and the trend of restrictive diets

Currently, eliminating gluten from the diet has become a massive wellness trend, often promoted as a panacea for weight loss, improved energy, or reduced inflammation. However, medical science and precision nutrition warn us that this "blind" decision may not only be useless for most people, but potentially harmful by masking underlying health conditions or unintentionally altering the gut microbiota. The answer to whether or not a person should consume gluten lies not in social media trends, but in their individual genetic makeup and rigorous clinical diagnosis.

Gluten intolerance is not a single condition, but rather a spectrum of disorders ranging from celiac disease (a serious autoimmune disorder) to non-celiac gluten sensitivity (NCGS), including wheat allergy. Understanding the role our genes play, specifically the human leukocyte antigen (HLA) system, is the essential first step in personalizing our diet and determining with molecular precision whether gluten is a true biological enemy or a safe component of our food.

The HLA complex and predisposition to celiac disease: HLA-DQ2 and HLA-DQ8

Celiac disease is a chronic autoimmune enteropathy triggered by gluten ingestion in genetically predisposed individuals. The genetic basis of this disease is one of the most potent and well-known in modern medicine, closely linked to the HLA class II system, specifically to the heterodimeric molecules encoded by the HLA-DQB1 and HLA-DQA1 genes.

The role of the HLA-DQ2 heterodimer

Approximately 90-95% of celiac patients express the HLA-DQ2 molecule, encoded by the DQA1 alleles05 and DQB1O2 (in cis or trans configuration). This molecule has an extraordinary chemical affinity for binding to gliadin peptides (the gluten storage protein) once they have been modified (deamidated) by the intestinal tissue transglutaminase enzyme. The binding of HLA-DQ2 to the deamidated peptide aggressively activates T cells of the immune system, triggering a destructive inflammatory response that atrophies the villi of the intestinal mucosa, severely compromising nutrient absorption.

The role of the HLA-DQ8 heterodimer

The remaining celiac patients (5-10%) express the HLA-DQ8 molecule, encoded by the DQA1 alleles03 and DQB10302. Although with a slightly different molecular structure than HLA-DQ2, the HLA-DQ8 molecule also has an optimal three-dimensional structure for the presentation of deamidated gluten peptides to immune cells, triggering the same harmful autoimmune cascade.

The value of the negative predictive value (NPV)

The most crucial aspect that nutritionists and users should understand about the HLA genetic test is its negative predictive value (NPV), which is nearly 991. This means that if the Oorenji genetic test (https://oorenji.com) reveals that a user is negative for the alleles that code for HLA-DQ2 and HLA-DQ8, the probability of them developing celiac disease during their lifetime is practically zero (less than 11). Conversely, having these risk alleles is not a diagnosis of the disease: around 30-401% of the general healthy population carries HLA-DQ2/DQ8 without ever developing the disease. Genetics determines the predisposition, but other environmental and epigenetic factors, as well as the microbiome, act as triggers for the pathology.

Non-celiac gluten sensitivity (NCGS): Beyond autoimmunity

What about patients who experience bloating, fatigue, brain fog, and abdominal pain after consuming gluten, but whose blood tests (negative specific antibodies), intestinal biopsies (healthy mucosa), and genetic tests for celiac disease are normal? In these cases, clinical suspicion shifts toward Non-Celiac Gluten Sensitivity (NCGS).

The innate immune mechanism of NCGS

Unlike celiac disease, which is a directed adaptive and autoimmune immune response, non-celiac gluten sensitivity (NCGS) appears to be mediated by activation of the innate immune system. Recent research suggests that wheat gliadin activates direct inflammatory signaling pathways at the intestinal barrier, stimulating the release of pro-inflammatory cytokines and transiently increasing intestinal permeability.

Furthermore, it has been discovered that gluten may not be the sole culprit in non-congestive gluten syndrome (NCGS). Other components of wheat, such as amylase-trypsin inhibitors (ATIs)—defense proteins in cereal grains capable of stimulating innate immune receptors—and fructans (fermentable carbohydrates known as FODMAPs), play a fundamental role in generating digestive symptoms. The nutrigenomic test and the comprehensive Oorenji analysis allow for the differentiation of these profiles to determine whether the optimal intervention consists of strict gluten exclusion or a temporary low-FODMAP diet.

The importance of the microbiota in gluten tolerance

The gut microbiota is the critical mediator between the components of our diet and the immune system's response. In the context of gluten, the health and diversity of our microbial ecosystem largely determine the threshold of immunological tolerance.

Microbial digestion of gluten and modulation of the barrier

Certain beneficial bacteria in the colon, such as some strains of Lactobacillus and BifidobacteriumThey possess peptidase enzymes that cooperate with human digestive enzymes to more completely break down large, indigestible gliadin molecules, reducing the immune system's exposure to highly immunogenic peptides. Furthermore, a balanced gut microbiota produces high levels of butyrate (a short-chain fatty acid), which nourishes colonocytes, strengthens the tight junctions of the intestinal barrier, and actively inhibits local inflammatory processes. When dysbiosis (a gut microbiota imbalance) is present, the intestinal barrier weakens, facilitating the passage of partially digested peptides that can pathologically trigger the immune system.

Practical application in Oorenji: The precision approach

At Oorenji (https://oorenji.com), we address the dilemma of gluten sensitivity from a precision translational medicine perspective, combining genetic analysis, the user's clinical symptom profile, and active monitoring of their habits.

Oorenji's Clinical Decision Algorithm

When a user performs a nutrigenomic profile with Oorenji:

1. Direct Genetic Evaluation: The HLA-DQ2 and HLA-DQ8 status is rigorously analyzed. If the result is negative, the algorithm eliminates the suspicion of present or future celiac disease with a 99% safety rating, avoiding unjustified gluten restrictions that impoverish the microbiota and increase the cost of the shopping basket.
2. Symptomatic correlation and biomarkers: If the user carries risk variants (HLA-DQ2/DQ8) and reports compatible digestive symptoms, the platform proactively alerts and guides them to see a specialist doctor to complete the formal diagnosis before permanently removing gluten (which would falsify classic diagnostic tests).
3. Precision tailored nutrition: In the event of a confirmed non-celiac sensitivity or after the safe exclusion of gluten, Oorenji designs personalized dietary plans rich in naturally gluten-free pseudocereals (such as quinoa, buckwheat, and amaranth) and with a high density of prebiotic fiber to restore and protect the gut microbiota in a sustained manner.

Conclusion: Genetic rigor versus self-diagnosis

Deciding to unilaterally eliminate gluten based on a trend or self-diagnosis is a strategic health mistake. Your DNA contains the exact map of your biological predisposition. Using Oorenji's advanced platform allows you to decipher whether your digestive system is designed to safely tolerate wheat or if you require precise dietary adjustments. Basing your food choices on the strength of your genetics is the smartest way to regain your digestive well-being, avoid nutritional deficiencies, and enjoy a full and healthy life backed by real science.

Scientific references

• Sollid, L.M., & Lie, B.A. (2005). Celiac disease genetics: current concepts and practical applications. Clinical Gastroenterology and Hepatology, 3(9), 843-851.
• Catassi, C., Bai, JC, Bonaz, B., Bouma, G., … & Fasano, A. (2013). Non-celiac gluten sensitivity: the new frontier of gluten-related disorders. Nutrients, 5(10), 3839-3853.
• Junker, Y., Zeissig, S., Kim, SJ, Barisani, D., … & Schuppan, D. (2012). Wheat amylase-trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. Journal of Experimental Medicine, 209(13), 2395-2407.
• Caminero, A., Galipeau, HJ, McCarville, JL, Johnston, KL, … & Verdu, EF (2016). Duodenal bacteria from patients with celiac disease and healthy controls differentially cleave gluten peptides and affect immunogenicity. Gastroenterology, 151(4), 670-681.
• Palou, A., & Palou, M. (2021). Nutrigenomics and nutrigenetics: the clinical translation of precision nutrition. Journal of Clinical Medicine, 10(12), 2611.